HC Wainwright Has Pessimistic View of KYMR FY2025 Earnings

Key Points

• HC Wainwright has cut its FY2025 earnings per share estimate for Kymera Therapeutics from ($3.09) to ($3.26), while maintaining a "Buy" rating and a target price of $60.
• Kymera Therapeutics shares recently rose by 2.2%, trading at $42.48, with a market capitalization of $3.04 billion.
• Multiple analysts have provided differing price targets for Kymera, with the range from $51.00 to $72.00, indicating a generally positive outlook from the research community.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for Kymera Therapeutics in a research report issued on Tuesday, August 12th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($3.26) for the year, down from their prior forecast of ($3.09). HC Wainwright has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics' FY2026 earnings at ($3.37) EPS, FY2027 earnings at ($3.66) EPS, FY2028 earnings at ($3.71) EPS and FY2029 earnings at ($3.36) EPS.

Several other equities analysts have also issued reports on KYMR. UBS Group cut their target price on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen lowered Kymera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Wells Fargo & Company cut their target price on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, June 26th. BTIG Research reiterated a "buy" rating and issued a $59.00 target price on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Finally, Bank of America upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a research note on Monday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $59.11.

Kymera Therapeutics Stock Performance

KYMR traded down $0.22 on Friday, hitting $42.35. The company had a trading volume of 466,532 shares, compared to its average volume of 745,249. The stock has a fifty day moving average price of $44.44 and a 200-day moving average price of $36.51. Kymera Therapeutics has a 12-month low of $19.44 and a 12-month high of $53.27. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of -12.20 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $11.48 million for the quarter, compared to analysts' expectations of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business's quarterly revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.58) EPS.

Institutional Trading of Kymera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KYMR. Farther Finance Advisors LLC increased its position in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock valued at $27,000 after buying an additional 540 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares in the last quarter. State of Wyoming purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth approximately $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth approximately $55,000. Finally, KBC Group NV increased its position in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after purchasing an additional 328 shares in the last quarter.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the sale, the chief executive officer directly owned 660,482 shares in the company, valued at $32,363,618. The trade was a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elena Ridloff sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total value of $553,200.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,349 shares of company stock valued at $2,334,301. 16.01% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.